References

1. Blakely RD, Berson HE, Fremeau RT et al. Cloning and expression of a functional serotonin transporter from rat brain. Nature 1991; 354:66-70.

2. Hoffman BJ, Mezey E, Brownstein M. Cloning of a serotonin transporter affected by antidepressants. Science 1991; 249:1303-1306.

3. Uhl GR, Hartig PR. Transporter explosion: Update on uptake. Trends Pharmacol Sci 1992; 13:421-425.

4. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029.

5. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9:19-26.

6. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984; 230:94-102.

7. Lesch KP, Wolozin BL, Estler HC et al. Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm 1993; 91:67-72.

8. Lesch KP, Wolozin BL, Murphy DL et al. Primary structure of the human platelet serotonin uptake site—Identity with the brain serotonin transporter. J Neurochem 1993; 60:2319-2322.

9. Artigas F, Romero L, de Montigny C et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19:378-383.

10. Scuvee-Moreau J, Dresse A. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat. Eur J Pharmacol 1979; 57:219-225.

11. Quinaux N, Scuvee-Moreau J, Dresse A. Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants; correlation with reduction of spontaneous firing rate of central monoaminergic neurones. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 319:66-70.

12. Blier P, de Montigny C. Electrophysiological investigations on the effect of repeated zimeldine administration on serotonergic neurotransmission in the rat. J Neurosci 1983; 3:1270-1278.

13. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatment: Implications for the therapeutic response in major depression. J Clin Psycho-pharmacol 1987; 7:24S-35S.

14. Adell A, Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 1991; 343:237-244.

15. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialysis study. Eur J Pharmacol 1992; 229:101-103.

16. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentration of serotonin in the dorsal raphe prevents the drug's effect in frontal cortex. Brain Res 1992; 584:322-324.

17. Gartside SE, Umbers V, Hajos M et al. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995; 115:1064-1070.

18. Malagié I, Trillat AC, Jacquot C et al.. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: An in vivo microdialysis study. Eur J Pharmacol 1996; 286:213-217.

19. Romero L, Artigas F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors. J Neurochem 1997; 68:2593-2603.

20. Cortés R, Soriano E, Pazos A et al.. Autoradiography of antidepressant binding sites in the human brain: Localization using [3H]imipramine and [3H]paroxetine. Neurosci 1988; 27:473-496.

21. Hrdina PD, Foy B, Hepner A et al. Antidepressant binding sites in brain: Autoradiographic comparison of [3H]paroxetine and [3H]imipramine, localization and relationship to serotonin transporter. J Pharmacol Exp Ther 1990; 252:410-418.

22. Héry F, Faudon M, Ternaux JP. In vivo release of serotonin in two raphe nuclei (raphe dorsalis and magnus) of the cat. Brain Res Bull 1982; 8:123-129.

23. Adell A, Carceller A, Artigas F. In vivo brain dialysis study of the somatodendritic release of serotonin in the raphe nuclei of the rat. Effects of 8-hydroxy-2-(di-n-propyl-amino)tetralin. J Neurochem 1993; 60:1673-1681.

24. Bosker F, Klompmakers A, Westenberg H. Extracellular 5-hydroxytryptamine in median raphe nucleus of the conscious rat is decreased by nanomolar concentrations of 8-hydroxy-2-(di-n-propylamino)tetralin and is sensitive to tetrodotoxin. J Neurochem 1994; 63:2165-2171.

25. Matos FF, Urban C, Yocca FD. Serotonin (5-HT) release in the dorsal raphé and ventral hippocampus: raphé control of somatodendritic and terminal 5-HT release. J Neural Transm 1996; 103:173-190.

26. Halliday G, Harding A, Paxinos G. Serotonin and Tachykinin Systems. In: Paxinos G, ed. The Rat Nervous System, 2nd ed. Sydney: Academic Press, 1995:929-974.

27. a) Hervás I, Artigas F. Effect of fluoxetine on extracellular 5-hydroxytryptamine in the rate brain. Role of 5-HT autoreceptors. Eur J Pharmacol 1998; 358:9-18.

27. b) Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Compact Third Edition. Orlando; Academic Press 1997.

28. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 1985; 346:205-230.

29. Sotelo C, Cholley B, El Mestikawy S et al. Direct immunohistochemical evidence of the existence of 5-HT autoreceptors on serotonergic neurons in the midbrain raphe nuclei. Eur J Neurosci 1990; 2:1144-1154.

30. Pompeiano M, Palacios JM, Mengod G. Distribution and cellular localization of mRNA coding for 5-HTiA receptor in the rat brain: Correlation with receptor binding. J Neurosci 1992; 12:440-453.

31. Andrade R, Malenka RC, Nicoll RA. A G protein couples serotonin and GABAb receptors to the same channel in hippocampus. Science 1986; 234:1261-1265.

32. Innis RB, Aghajanian GK. Pertussis toxin blocks 5-HT1a and GABAb receptor-mediated inhibition of serotonergic neurons. Eur J Pharmacol 1987; 143:195-204.

33. De Vivo M, Maayani S. Characterization of the 5-hydroxytryptamine 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea-pig and rat hippocampal membranes. J Pharmacol Exp Ther 1986; 238:248-253.

34. Markstein R, Hoyer D, Engel G. 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 333:335-341.

35. Clarke WP, Yocca FD, Maayani S. Lack of 5-hydroxytryptamine(1A)- mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J Pharmacol Exp Ther 1996; 277:1259-1266

36. Hutson PH, Sarna GS, O'Connell MT et al. Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci Lett 1989; 100:276-280.

37. Invernizzi R, Carli M, Di Clemente A et al. Administration of 8-hydroxy-2-(di-n-propyl-amino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity. J Neurochem 1991; 56:243-247.

38. Romero L, Casanovas JM, Hervas I et al. Strategies to optimize the antidepressant action of selective serotonin reuptake inhibitors. In: Skolnick P, ed. Antidepressants: Current Trends and Future Directions, Totowa; New Jersey: Humana Press, 1997:1-33.

39. Romero L, Celada P, Artigas F. Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/Go proteins in dorsal raphe nucleus. Eur J Pharmacol 1994; 265:103-106.

40. Romero L, Bel N, Artigas F et al. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacol 1996; 15:349-360.

41. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15:220-226.

42. Arborelius L, Nomikos GG, Grillner P et al. 5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 352:157-165.

43. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978; 179:641-668.

44. McQuade R, Sharp T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem 1997; 69:791-796.

45. Casanovas JM, Artigas F. Differential effects of ipsapirone on 5-HT release in the dorsal and median raphe neuronal pathways. J Neurochem 1996; 67:1945-1952.

46. Casanovas JM, Lesourd M, Artigas F. The selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT reduce extracellular 5-hydroxytryptamine in rat brain in a regionally-selective manner. Br J Pharmacol 1997; 122:733-741.

47. Rutter JJ, Auerbach SB. Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther 1993; 265:1319-1324.

48. Hjorth S, Auerbach SB. Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 1994; 260:251-255.

49. Auerbach SB, Lundberg JF, Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacol 1995; 34:89-96.

50. Hjorth S, Auerbach SB. 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res 1996; 73:281-283.

51. Sin ton CM, Fallon SL. Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor. Eur J Pharmacol 1988; 157:173-181.

52. Hajos M, Gartside SE, Sharp T. Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 351:624-629.

53. Kreiss DS, Lucki I. Differential regulation of 5-HT release in the striatum and hippocampus by 5-HTiA autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther 1994; 269:1268-1279.

54. Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 1989; 69:864-989.

55. Middlemiss DN. Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur J Pharmacol 1984; 101:289-293.

56. Moret C, Briley M. 5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus. Neuropharmacology 1997; 36:1713-1723

57. Davidson C, Stamford JA. Serotonin efflux in the rat ventral lateral geniculate nucleus assessed by fast cyclic voltammetry is modulated by 5-HT1B and 5-HT1D autoreceptors. Neuropharmacology 1996; 35:1627-1634.

58. Trillat AC, Malagie I, Scearce K et al. Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HTiB receptors: In vivo microdialysis studies. J Neurochem 1997; 69:2019-2025.

59. Goodwin GM, de Souza RJ, Green AR. Presynaptic serotonin receptor-mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock. Nature 1985; 317:531-533.

60. Hensler JG, Covachich A, Frazer A. A quantitative autoradiographic study of serotonin 1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 1991; 4:131-144.

61. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15:243-245.

62. Bosker FJ, Vanesseveldt KE, Klompmakers AA et al. Chronic treatment with fluvoxamine by osmotic minipumps fails to induce persistent functional changes in central 5-HT(1A) and 5-HT(1B) receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacol 1995; 117:358-363.

63. Invernizzi R, Bramante M, Samanin R. Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: Role of presynaptic 5-HT1A receptors. Eur J Pharmacol 1994; 260:243-246.

64. Invernizzi R, Bramante M, Samanin R. Extracellular concentrations of serotonin in the dorsal hippocampus after acute and chronic treatment with citalopram. Brain Res 1995; 696:62-66.

65. Rutter JJ, Gundlah C, Auerbach SB. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994; 171:183-186.

66. Arborelius L, Nomikos GG, Hertel P et al. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 353:630-640.

67. Artigas F. 5-HT and antidepressants: New views from microdialysis studies. Trends Pharmacol Sci 1993; 14:262.

68. Hjorth S. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study. J Neurochem 1993; 60:776-779.

69. Dreshfield LJ, Wong DT, Perry KW et al. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HTiA receptors. Neurochem Res 1996; 21:557-562.

70. Romero L, Hervas I, Artigas F. The 5-HT1A antagonist WAY 100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 1996; 219:123-126.

71. Invernizzi R, Velasco C, Bramante M et al. Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology 1997; 36:467-473.

72. Malagié I, Trillat AC, Douvier E et al. Regional differences in the effect of the combined treatment of WAY 1GG635 and fluoxetine. An in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354:785-790.

73. Tao R, Auerbach SB. Anesthetics block morphine-induced increases in serotonin release in rat CNS. Synapse 1994; 18:307-314.

74. Sánchez C. Interaction studies of 5-HT1A receptor antagonists with selective 5-HT reuptake inhibitors in isolated aggressive mice. Eur J Pharmacol 1997; 334:127-132.

75. Zhou FC, McKinzie DL, Patel TD et al. Additive reduction of alcohol drinking by 5-HT1A antagonist WAY 1GG635 and serotonin uptake blocker fluoxetine in alcohol-preferring rats. Alcohol Clin Exp Res 1998; 22:266-269

76. Hashimoto S, Inoue T, Koyama T. Effects of the coadministration of 5-HT1A receptor antagonists with an SSRI in conditioned fear stress-induced freezing behavior. Pharmacol Biochem Behav 1997; 58:471-475.

77. Li DL, Simmons RMA, Iyengar S. 5-HT(1A) receptor antagonists enhance the functional activity of fluoxetine in a mouse model of feeding. Brain Res 1998; 781:91-99

78. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51:248-251.

79. Lesch KP, Poten B, Sohnle K et al. Pharmacology of the hypothermic response to 5-HT1A receptor activation in humans. Eur J Clin Pharmacol 199G; 39:17-19.

80. Meltzer HY, Maes M. Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology 1994; 114:635-643.

81. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222.

82. Dinan TG, Scott JV. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors. J Serotonin Res 1996; 3:119-121.

83. Vinar O, Vinarova E, Horacek J. Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression. Homeostasis 1996; 37:93-95.

84. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affective Disord 1996; 41:201-210.

85. Bakish D, Hooper CL, Thornton MD et al. Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol 1997; 12:91-97.

86. Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1a receptors induces rapid antidepressant response. Neuropsychopharmacol 1997; 16:333-338.

87. Kraus RP. Pindolol augmentation of tranylcypromine in psychotic depression. J Clin Psychopharmacol 1997; 17:225-226.

88. Berman RM, Darnell AM, Miller HL et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial. Am J Psychiatry 1997;154:37-43.

89. Pérez V, Gilaberte I, Faries D et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment The Lancet 1997; 349:1594-1597.

9G. Thomas P, Bordet R, Alexandre JY et al. Pindolol addition shortens delay of action of paroxetine in major depression: A double blind controlled study. Eur Neuropsychopharmacol 1997; 7(Suppl 2):S173.

91. Tomé MB, Isaac MT, Harte R et al. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12:81-89.

92. Zanardi R, Artigas F, Franchini L et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997; 17:446-450.

93. Moreno FA, Gelenberg AJ, Bachar K et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997; 58:437-439.

93. a) Zanardi R, Franchini L, Gasperinin M et al. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol 1998; 18:441-446.

93. b) Bordet R, Thomas P, Dupuis B et al. Reseau de Recherche et d'Experimentation Psychopharmacologique. effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind; placebo-controlled trail. Am J Psychiatry 1998; 155:1346-1351.

93. c) Maes M, LIbbrecht I, van Hunsel et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999; 19:177-182.

93. d) Pérez V, Soler j, Puigdemon D et al. Grup de Recerca en Trastoms Afectius. A doubleblind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999; 56:375-379.

94. Frishman WH. Pindolol: A new beta-adrenoceptor antagonist with partial agonist activity. New Eng J Med 1983; 308 (16):941-944.

95. Meltzer HY, Maes M. Effect of pindolol on hormone secretion and body temperature: Partial agonist effects. J Neural Transm 1996; 103:77-88.

96. Hoyer D, Schoeffter P. 5-HT receptors: Subtypes and second messengers. J Receptor Res 1991;11:197-214.

97. Avorn J, Everitt DE, Weiss D. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986; 255:357-360.

98. Thiessen BQ, Walace SM, Blackburn JL. Increased prescribing of antidepressants subsequent to ß-blocker therapy. Arch Intern Med 1990; 150:2286-2290.

99. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980; 210:88-90.

100. Palvimaki EP, Laakso A, Kuoppamaki M et al. Up-regulation of beta(1)-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology 1994; 115:543-546.

101. Seifritz E, Stahl SM, Gillin JC. Human sleep EEG following the 5-HT1A antagonist pindolol: Possible disinhibition of raphe neuron activity. Brain Res 1997; 759:84-91

102. Corradetti R, Laaris N, Hamoun N et al. Antagonist properties of (-)pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br J Pharmacol 1998; 123:449-452.

103. Drevets WC, Price JL, Simpson JR et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386:824-827.

104. Biver F, Wikler D, Lostra F et al. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br J Psychiatry 1997; 171:444-448.

Defeat Depression

Defeat Depression

Learning About How To Defeat Depression Can Have Amazing Benefits For Your Life And Success! Discover ways to cope with depression and melancholic tendencies! Depression and anxiety particularly have become so prevalent that it’s exceedingly common for individuals to be taking medication for one or even both of these mood disorders.

Get My Free Ebook


Post a comment